Clinical Trial Update: Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing the efficacy and safety of ruxolitinib in adults with grade II-IV steroid-refractory acute graft-versus-host disease; currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Jakafi (Ruxolitinib) (Ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Steroid-refractory Acute Graft Versus Host Disease | Phase 4 | Status: RECRUITING